Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy
Authors' conclusion
Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD.
Study context
- Population
- Patients with familial partial lipodystrophy (FPLD) (aged 58 ± 12 years; 76.47% female) and patients with T2D (aged 58 ± 13 years; 71% female) starting GLP-1 RA
- Participants
- 14 vs 14
- Exposure
- GLP-1 RA in FPLD vs T2D, before and 6 months after starting
- FPLDn = 14
- Type 2 diabetes mellitus (DM)n = 14reference
- Outcome
- Change in FPLD before vs 6 months after starting GLP-1 RA
- Follow-up
- 6 months
Main finding
As reported in the abstract
Weight reduction in FPLD, kg (mean ± SD), before to after; P = 0.002
95 ± 23 to 91 ± 22
BMI reduction in FPLD, kg/m² (mean ± SD), before to after; P = 0.001
33 ± 6 to 31 ± 6
HbA1c reduction in FPLD (mean ± SD), before to after; P = 0.02
8.2% ± 1.4% to 7.7% ± 1.4%
Fasting glucose reduction in FPLD, mg/dL (mean ± SD), before to after; P = 0.04
186 ± 64 to 166 ± 53
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Change in TG after treatmentChange greater with FPLD | P = 0.02 |
Safety
- Acute pancreatitis · with longer therapy — FPLD
- 2 events
Original publication
Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →